Identification of a serotonin/glutamate receptor complex implicated in psychosis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The psychosis associated with schizophrenia is characterized by alterations in sensory processing and perception. Some antipsychotic drugs were identified by their high affinity for serotonin 5-HT2A receptors (2AR). Drugs that interact with metabotropic glutamate receptors (mGluR) also have potential for the treatment of schizophrenia. The effects of hallucinogenic drugs, such as psilocybin and lysergic acid diethylamide, require the 2AR and resemble some of the core symptoms of schizophrenia. Here we show that the mGluR2 interacts through specific transmembrane helix domains with the 2AR, a member of an unrelated G-protein-coupled receptor family, to form functional complexes in brain cortex. The 2AR-mGluR2 complex triggers unique cellular responses when targeted by hallucinogenic drugs, and activation of mGluR2 abolishes hallucinogen-specific signalling and behavioural responses. In post-mortem human brain from untreated schizophrenic subjects, the 2AR is upregulated and the mGluR2 is downregulated, a pattern that could predispose to psychosis. These regulatory changes indicate that the 2AR-mGluR2 complex may be involved in the altered cortical processes of schizophrenia, and this complex is therefore a promising new target for the treatment of psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34];”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Temporal pattern encoding relieves the cellular information bottleneck, where many stimuli must signal through few intracellular pathways to generate diverse and specific cellular responses (30 -32) but complicates the relationship between synthetic target modulators and their cellular and clinical effects.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several recent studies of drugs acting at cell surface receptor targets show that the activation mechanisms responsible for their cellular and systemic effects are more complex than accounted for by their classical pharmacological profiles (30 -32).”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled Receptor
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., Kobilka, T. S., Choi, H.-J., Kuhn, P., Weis, W. I., Kobilka, B. K., et al. (2007) · Science · doi:10.1126/science.1150577 · Cited by 3,264
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Self-citation
Cited by
Items 501–600 of 835
Immunological Effects of Ayahuasca in Humans
dos Santos, R. G. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.960113 · Cited by 18
Class A and C GPCR Dimers in Neurodegenerative Diseases
Moreira, I. S., Caniceiro, A. B., Bueschbell, B., & Schiedel, A. C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327221830 · Cited by 21
Ahnaou, A., Lavreysen, H., Tresadern, G., Cid, J. M., & Drinkenburg, W. H. I. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144017 · Cited by 19
Nisenbaum, L., Downing, A. M., Zhao, F., Millen, B. A., Munsie, L. M., Kinon, B. J., Adams, D. H., Gomez, J., & Penny, M. A. (2016) · Journal of Personalized Medicine · doi:10.3390/jpm6010009 · Cited by 18
“Further evidence for crosstalk between both receptors lies in the fact that in 5-HT2A knockout mice, an attenuation of the locomotor activity induced by the mGlu2/3 receptor antagonist LY341495 is observed [20].”
BackgroundNovel signaling of dynorphin at κ-opioid receptor/bradykinin B2 receptor heterodimers
Ji, B., Liu, H., Zhang, R., Jiang, Y., Wang, C., Li, S., Chen, J., & Bai, B. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.01.005 · Cited by 19
“Several studies report that hallucinogenic 5-HT2A receptor agonists activate both Gq and Gi proteins when the 5-HT2A receptor forms heteromers with the mGlu2 receptor [58, 59].”
BackgroundG Protein-Coupled Receptor Heteromers as Putative Pharmacotherapeutic Targets in Autism
DelaCuesta-Barrutia, J., Peñagarikano, O., & Erdozain, A. M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.588662 · Cited by 18
Cortical influences of serotonin and glutamate on layer V pyramidal neurons
Marek, G. J., & Schoepp, D. D. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2020.11.002 · Cited by 20
Continuing challenges in targeting oligomeric GPCR-based drugs
Botta, J. A., Appelhans, J., & McCormick, P. J. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.11.009 · Cited by 19
Wischhof, L., Aho, H. E. A., & Koch, M. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.011 · Cited by 20
Neurobehavioral Profiles of Six Genetically-based Rat Models of Schizophrenia- related Symptoms
Oliveras, I., Cañete, T., Sampedro-Viana, D., Río-Álamos, C., Tobeña, A., Corda, M. G., Giorgi, O., & Fernández‐Teruel, A. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230221093644 · Cited by 17
“…1 ( NGR1 ) heterozygous mice, the transgenic mice containing inducible and/or partial DISC1 (susceptibility gene disrupted-in-schizophrenia-1) gene mutations, the dopamine transporter knockout mice, the calcineurin ( CN ) knockout mice and the 5-HT2A and glutamate receptor knockouts [2, 3, 5, 7].”
BackgroundBueschbell, B., Magalhães, P. R., Barreto, C. A. V., Melo, R., Schiedel, A. C., Machuqueiro, M., & Moreira, I. S. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.08.032 · Cited by 17
Non-canonical interplay between glutamatergic NMDA and dopamine receptors shapes synaptogenesis
Bénac, N., Saraceno, G. E., Butler, C., Kuga, N., Nishimura, Y., Yokoi, T., Su, P., Sasaki, T., Petit‐Pedrol, M., Galland, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44301-z · Cited by 17
X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?
Topiol, S. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.783815 · Cited by 17
“3 Dimerization With the increased awareness of the physiological role of dimerization and multimerization of GPCRs [80-82,109], the GPCR X-ray structures may provide new opportunities for rational drug design to control this phenomenon.”
BackgroundSoriano-Ursua, M. A., Trujillo-Ferrara, J. G., & Correa‐Basurto, J. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900419a · Cited by 18
Hallucinogens in Drug Discrimination
Baker, L. E. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_476 · Cited by 18
“Of particular interest is evidence indicating the involvement of group II glutamate receptors (mGluR2/3) in mediating hallucinogenic effects (González-Maeso et al. 2007, 2008; Delille et al. 2012; Moreno et al. 2011; Winter et al. 2004; Carbonaro et al. 2015).”
BackgroundAzizi, H., Hwang, J., Suen, V. M. M., Kang, N. Z., Somvanshi, R. K., Tadavarty, R., Kumar, U., & Sastry, B. R. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.06.053 · Cited by 17
Li, W., Jin, J., Xiong, T., Yu, P., & Mao, L. (2022) · Angewandte Chemie · doi:10.1002/ange.202204134 · Cited by 17
Target practice: HDAC inhibitors for schizophrenia
Hyman, S. E. (2012) · Nature Neuroscience · doi:10.1038/nn.3200 · Cited by 19
Lee, M.-Y., Chiang, C., Chiu, H., Chan, M., & Chen, H. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.006 · Cited by 17
Natural Psychoplastogens As Antidepressant Agents
Benko, J., & Vranková, S. (2020) · Molecules · doi:10.3390/molecules25051172 · Cited by 19
“This leads to inhibition of either phospholipase A2 (PLA2) or PLCβ, respectively [51].”
BackgroundArias, H. R., Micheli, L., Jensen, A. A., Galant, S., Vandermoere, F., Venturi, D., Manetti, D., Romanelli, M. N., Ghelardini, C., Marin, P., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117887 · Cited by 16
Functional Selectivity in GPCR Heterocomplexes
González‐Maeso, J., & Sealfon, S. C. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712800959152 · Cited by 17
“It was recently reported that 5-HT2A and mGlu2 are co-expressed in cortical pyramidal neurons, and that they form a GPCR heterocomplex in human frontal cortex [43] and in tissue cultures [43,44].”
Self-citationPoulie, C. B. M., Liu, N., Jensen, A. A., & Bunch, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01058 · Cited by 16
Role of Antibodies in Developing Drugs That Target G‐Protein‐Coupled Receptor Dimers
Hipser, C., Bushlin, I., Gupta, A., Gomes, I., & Devi, L. A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20199 · Cited by 16
Molecular Dynamics Simulations of G Protein‐Coupled Receptors
Bruno, A., & Costantino, G. (2012) · Molecular Informatics · doi:10.1002/minf.201100138 · Cited by 19
Nakazawa, S., Yokoyama, C., Nishimura, N., Horisawa, T., Kawasaki, A., Mizuma, H., Doi, H., & Onoe, H. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2815-9 · Cited by 18
“Chronic administration of clozapine, but not haloperidol, reportedly causes a decrease in [3H]ketanserin binding and reduced 5- HT2A receptor mRNA expression in the rodent somatosensory cortex (González-Maeso et al. 2008).”
BackgroundPotentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex
Labonté, B., Bambico, F. R., & Gobbi, G. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0446-4 · Cited by 18
“These in vivo results suggest that the GLU system and 5-HT2A receptors maintain functional interactions (Gonzalez-Maeso et al. 2008) and support the fact that these interactions are relevant to psychosis and to antipsychotic treatment.”
BackgroundResultExploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone
Romantini, N., Alam, S., Dobitz, S., Spillmann, M., Foresta, M. D., Schibli, R., Schertler, G. F. X., Wennemers, H., Deupí, X., Béhé, M. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108776118 · Cited by 15
“For example, the class C GPCRs GABAB1 and GABAB2 are linked together by a cytoplasmic coiled coil to form a functional GABAB receptor dimer, whereas 5-HT2A and mGluR2 interact through their transmembrane helices (9, 10).”
BackgroundQuaternary Structure Predictions and Structural Communication Features of GPCR Dimers
Fanelli, F., Seeber, M., Felline, A., Casciari, D., & Raimondi, F. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386931-9.00005-2 · Cited by 16
Lazim, R., Suh, D., Lee, J. W., Vu, T. N. L., Yoon, S.-H., & Choi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063241 · Cited by 15
Role of metabotropic glutamate receptors in CNS disorders
O’Connor, R. M., & Cryan, J. F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511760334.017 · Cited by 16
Ehrlich, A. T., Furuyashiki, T., Kitaoka, S., Kakizuka, A., & Narumiya, S. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087288 · Cited by 18
“In another example, the serotonin 2A receptor forms a complex with the metabotropic glutamate receptor 2 through a specific transmembranedomain (González-Maeso et al., 2008).”
BackgroundHan, S., Cui, Q., Guo, X., Fan, Y., Guo, J., Zong, X., Hu, M., Lu, F., Chen, X., & Chen, H. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.006 · Cited by 16
The role of experimental and computational structural approaches in 7TM drug discovery
Topiol, S., & Sabio, M. L. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1072166 · Cited by 15
“Indeed, 5HT 2a hetero-dimerization with mGluR2 has been implicated in CNS disease [38] .”
BackgroundIglesias, A., Cimadevila, M., de la Fuente, R. A., Martí-Solano, M., Cadavid, M. I., Castro, M., Selent, J., Loza, M. I., & Brea, J. M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.011 · Cited by 14
“The serotonin 2A receptor (5-HT2A) is a class A GPCR associated with schizophrenia as an important target for atypical antipsychotic drugs (González-Maeso et al., 2008; Roth et al., 1998).”
BackgroundMirchandani‐Duque, M., Choucri, M., Hernández-Mondragón, J. C., Crespo‐Ramírez, M., Pérez-Olives, C., Ferraro, L., Franco, R., de la Mora, M. P., Fuxé, K., & Borroto‐Escuela, D. O. (2024) · Membranes · doi:10.3390/membranes14050096 · Cited by 16
Analysis of Receptor–Receptor Interaction by Combined Application of FRET and Microscopy
Prasad, S., Zeug, A., & Ponimaskin, E. G. (2013) · Methods in cell biology · doi:10.1016/b978-0-12-408143-7.00014-1 · Cited by 14
Interaction of Membrane Cholesterol with GPCRs: Implications in Receptor Oligomerization
Sengupta, D., Kumar, G. A., & Chattopadhyay, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-60174-8_16 · Cited by 15
“The potential implications of oligomerization are far reaching, specially keeping in mind the role of GPCRs as major drug targets [14].”
BackgroundDedeurwaerdere, S., Boets, S., Janssens, P., Lavreysen, H., & Steckler, T. (2014) · Acta Neurologica Belgica · doi:10.1007/s13760-014-0407-7 · Cited by 18
G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
Schmitz, G. P., & Roth, B. L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00397.2022 · Cited by 13
Philibert, C. E., Disdier, C., Lafon, P., Bouyssou, A., Oosterlaken, M., Galant, S., Pizzoccaro, A., Tuduri, P., Ster, J., Liu, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adg1679 · Cited by 14
“Neverthe-less, there is compelling evidence indicating that a fraction of mGlu 2 is also located post-synaptically, where it can associate with the serotonin 5-HT 2A receptor, another major target of antipsychotics ( 31 ).”
BackgroundEvaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
Vallano, A., Fernández‐Dueñas, V., García-Negredo, G., Quijada-Manuitt, M. Á., Simon, C. P., Cuffí, M. L., Carbonell, L., Sánchez, S., Arnau, J. M., & Ciruela, F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990115 · Cited by 14
“9 able to form homo- and heteromers at the plasma membrane level [52, 53], and while receptor homodimers require the formation of a covalent disulphide bridge between the extracellular N-terminal domain [53] the heteromerization might involve the transmembrane domains [54].”
BackgroundKawaura, K., Karasawa, J.-I., & Hikichi, H. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.05.027 · Cited by 13
“The mGlu2 receptor d 5-HT2A receptor have been reported to form a heterodimeric mplex [23].”
BackgroundEngel, M., Snikeris, P., Matosin, N., Newell, K. A., Huang, X., & Frank, E. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4230-0 · Cited by 15
“The expression of mGluR2/3 in cortical regions appears to vary between populations of patients, with reduced (Corti et al., 2007; Ghose et al., 2009; González-Maeso et al., 2008; Gupta et al., 2005) and unchanged levels being reported (Frank et al., 2011; Matosin et al., 2014).”
BackgroundDolder, P. C., Grünblatt, E., Müller, F., Borgwardt, S., & Liechti, M. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00423 · Cited by 13
“Indeed, a key mechanism of action of LSD is the activation of frontal cortex glutamate transmission secondary to 5-HT2A receptor stimulation (Gonzalez-Maeso et al., 2008; Moreno et al., 2011; Buchborn et al., 2015).”
BackgroundBartuzi, D., Kaczor, A. A., & Matosiuk, D. (2017) · Molecules · doi:10.3390/molecules22071188 · Cited by 14
“In particular, it is important to note that binding of an agonist with one monomer modulates agonist affinity to the other unit of this dimer [81] which may have physiological consequences—for instance, a heterodimer of serotonin 5-HT2A receptor and mGluR2 receptor is important in psychosis [82].”
BackgroundCasadó-Anguera, V., Cortés, A., Casadó, V., & Moreno, E. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1664469 · Cited by 13
“The 5-HT2AR-mGluR2 heteromer, target of hallucinogenic drugs, bias its signaling to more Gαi/o and less Gαq/11, upon DOI activation [153].”
BackgroundSampedro-Viana, D., Cañete, T., Sanna, F., Oliveras, I., Lavín, V., Torrecilla, P., Río-Álamos, C., Tapias-Espinosa, C., Sánchez-González, A., Tobeña, A., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06411-w · Cited by 13
Sharp, S. I., Hu, Y., Weymer, J. F., Rizig, M., McQuillin, A., Hunt, S. P., & Gurling, H. (2013) · Psychiatric Genetics · doi:10.1097/ypg.0b013e32835fe51d · Cited by 13
“In untreated schizophrenia patients, frontal cortical 5-HT2A receptors are upregulated relative to control (Gonzalez-Maeso et al., 2008) whereas in individuals with schizophrenia with a history of antipsychotic medication, there is reduced frontal cortical 5-HT2A protein and mRNA (Burnet et al.,…”
BackgroundSpecial biological issues in the management of women with schizophrenia
Kulkarni, J., Gavrilidis, E., Hayes, E., Heaton, V., & Worsley, R. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.62 · Cited by 16
Iglesias, A., Lage, S., Cadavid, M. I., Loza, M. I., & Brea, J. M. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116644162 · Cited by 12
“5-HT2A receptors are G protein–coupled receptors (GPCRs) that regulate multiple physiological functions and are relevant targets of atypical antipsychotic drugs.(1) 5-HT2A receptors were one of the first GPCRs for which the functional selectivity phenomenon was observed, with different ligands differentially activatin…”
BackgroundSerotonin 2A receptors and cannabinoids
Ibarra‐Lecue, I., Díez-Alarcia, R., & Urigüen, L. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.004 · Cited by 12
Metabotropic glutamate receptors in Parkinson's disease
Kwan, C., Kang, W., Kim, E., Belliveau, S., Frouni, I., & Huot, P. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.10.001 · Cited by 14
Chronic toxicity of broflanilide in Daphnia magna: changes in molting, behavior, and gene expression
Wang, K., Liang, Y., Duan, M., Che, W., & He, L. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-26255-3 · Cited by 12
Ubhayarathna, M., Langmead, C. J., Diepenhorst, N. A., & Stewart, G. D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16233 · Cited by 13
“:3) mice (Fribourg et al., 2011; González-Maeso et al., 2008).”
GPCR & Company: Databases and Servers for GPCRs and Interacting Partners
Kowalsman, N., & Niv, M. Y. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-7423-0_9 · Cited by 12
“In the last decade, it has become clear that many GPCRs may function as homo or heterodimers or higher order oligomers (Gonzalez-Maeso et al. 2008; Gorinski et al. 2012; Lohse 2010).”
BackgroundIntegrated structural modeling and super-resolution imaging resolve GPCR oligomers
Fanelli, F., Hanyaloglu, A. C., & Jonas, K. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.11.005 · Cited by 12
Serotonin and 5-HT2B receptors in microglia control of behavior
D’Andrea, I., Béchade, C., & Maroteaux, L. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00034-7 · Cited by 14
Nuara, S. G., Hamadjida, A., Kwan, C., Bédard, D., Frouni, I., Gourdon, J. C., & Huot, P. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02185-z · Cited by 12
Cieślik, P., & Wierońska, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228811 · Cited by 12
Kryszkowski, W., & Boczek, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071475 · Cited by 13
Bruno, A., Beato, C., & Costantino, G. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.27 · Cited by 14
Hudson, A., Thompson, K., MacNevin, P. D., Ivany, M., Teehan, M. D., Stuart, H. L., & Stewart, S. H. (2018) · Emerging Adulthood · doi:10.1177/2167696817748106 · Cited by 13
“epidemiologic study by Grant et al. (2004), 20% of respondents with a substance use disorder experienced comorbid mood/anxiety disorders, whereas proportions in the general population are closer to 5% for generalized anxiety disorder and depression (Kessler et al.”
BackgroundLin, H., Kim, J. G., Park, S. W., Noh, H. J., Kim, J., Yoon, C. Y., Woo, N.-S., Kim, B., Cho, S., Choi, B. H., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0073-6 · Cited by 12
Bortolato, A., Mobarec, J. C., Provasi, D., & Filizola, M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789824768 · Cited by 13
“Along these lines, in collaboration with experimental laboratories, we have recently contributed to the computational structural prediction of several GPCR oligomeric arrangements, including dopamine D2 homo-oligomers [27, 53], and the newly discovered serotonin 2A/metabotropic glutamate receptor 2 complex [54].”
BackgroundSelf-citationBruno, A., Costantino, G., Fabritiis, G. D., Pastor, M., & Selent, J. (2012) · PLoS ONE · doi:10.1371/annotation/b3d4540a-9b4b-4855-b570-6324b40232fe · Cited by 12
Billard, É., Torbey, A. G., Inserra, A., Grant, E., Bertazzo, A., Gregorio, D. D., Comai, S., Chatenet, D., Gobbi, G., & Hébert, T. E. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111588 · Cited by 11
Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons
Petrušková, A., Guhathakurta, D., Akdaş, E. Y., Perelló‐Amorós, B., Frischknecht, R., Weiss, E., Páleníček, T., & Fejtová, A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70020 · Cited by 11
“…activation of Gα i/o by psychedelics LSD and DOI was also shown to depend on the interaction of 5-HT2AR with metabotropic glutamate receptor mGluR2 (González-Maeso et al. 2008), and mGluR2 was demonstrated to be necessary for the pharmacological effects of DOI to take place (Moreno et al. 2011).…”
Integrin Triplets of Marine Sponges in Human Brain Receptor Heteromers
Tarakanov, A. O., Fuxé, K., & Borroto‐Escuela, D. O. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9793-6 · Cited by 11
Blockade of voltage-gated K+ currents in rat mesenteric arterial smooth muscle cells by MK801
Kim, J., Park, S. W., Lin, H. Y., Shin, K. C., Sung, D. J., Kim, J. G., Cho, H., Kim, B., & Bae, Y. M. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.11.005 · Cited by 11
Szafran‐Pilch, K., Faron‐Górecka, A., Kolasa, M., Żurawek, D., Szlachta, M., Solich, J., Kuśmider, M., & Dziedzicka‐Wasylewska, M. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.10.003 · Cited by 11
“There is evidence that GPCR heteromers may play a crucial role in psychiatric disorders like schizophrenia and antipsychotic drug action (Dziedzicka-Wasylewska et al., 2006b; Faron-Górecka et al., 2008; Gonzalez-Maeso et al., 2008) or Parkinson’s disease (Fuxe et al., 2003).”
G-protein coupled receptors and synaptic plasticity in sleep deprivation
Parmar, S., Tadavarty, R., & Sastry, B. R. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i11.954 · Cited by 11
Excitatory amino acids in neurological and neurodegenerative disorders.
Flores, G., Negrete-Díaz, J. V., Carrión, M., Andrade‐Talavera, Y., Bello, S. A., Sihra, T. S., & Rodríguez-Moreno, A. (2011) · CABI eBooks · doi:10.1079/9781845937980.0427 · Cited by 14
Menezes, M. M., Santini, M. A., Benvenga, M. J., Marek, G. J., Merchant, K., Mikkelsen, J. D., & Svensson, K. A. (2013) · Neuroscience Journal · doi:10.1155/2013/736439 · Cited by 12
“5-HT2AR and mGlu2 form a functional heteromeric complex, where activation of mGlu2 attenuates signaling through 5-HT 2AR [23].”
BackgroundFunctional associations among G protein-coupled neurotransmitter receptors in the human brain
Janušonis, S. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-16 · Cited by 15
“Among them, the complex between the metabotropic glutamate receptor mGluR2 and the serotonin receptor 5-HT2A has been particularly well studied, partly because of its potential importance in schizophrenia and other related brain disorders [32,59,60].”
BackgroundThe Serotonin Receptor Subtype 5b Specifically Interacts with Serotonin Receptor Subtype 1A
Niebert, S., van Belle, G. J., Vogelgesang, S., Manzke, T., & Niebert, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00299 · Cited by 12
PET Imaging of the 5-HT2A Receptor System: A Tool to Study the Receptor’s In Vivo Brain Function
Herth, M. M., & Knudsen, G. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-70474-6_5 · Cited by 16
Cisani, F., Roggeri, A., Olivero, G., Garrone, B., Tongiani, S., Giorgio, F. P. D., & Pittaluga, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01108 · Cited by 11
“This observation led to propose that the antipsychotic activity of mGlu2/3 agonists could in part rely on their ability to functionally antagonize the colocalized 5-HT2A receptors and, conversely, that pathological alterations of the mGlu2/3–5-HT2A receptor–receptor coupling could account for developing schizophrenia…”
BackgroundSnyder, S. H. (2008) · Nature · doi:10.1038/452038a · Cited by 11
Panaccione, I., Iacovelli, L., di Nuzzo, L., Nardecchia, F., Mauro, G., Janiri, D., Blasi, A. D., Sani, G., Nicoletti, F., & Orlando, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.029 · Cited by 11
Vollebregt, R., Storm, A. E. M., Lucassen, P. J., & Somers, M. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106529 · Cited by 11
Stachowicz, K., Wierońska, J. M., Domin, H., Chaki, S., & Pilc, A. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70603-x · Cited by 10
“The functional and structural interaction between mGlu2 and 5HT receptors is well-documented, and the interaction has been implicated in psychosis [11, 23, 26].”
BackgroundSelent, J., Bauer‐Mehren, A., López, L., Loza, M. I., Sanz, F., & Pastor, M. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060103 · Cited by 10
“Recent research (González-Maeso et al., 2008; Altar et al., 2009) confirms the complexity of the mechanisms involved in the disease.”
BackgroundMetamodulation of presynaptic NMDA receptors: New perspectives for pharmacological interventions
Olivero, G., Grilli, M., Marchi, M., & Pittaluga, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109570 · Cited by 10
Specific activation of mGlu2 induced IGF-1R transactivation in vitro through FAK phosphorylation
Hu, Y., Sun, Q., Zhang, W., Huo, Y.-J., Xu, C., & Liu, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0033-7 · Cited by 10
PACAP–PAC1 Signaling Regulates Serotonin 2A Receptor Internalization
Hayata‐Takano, A., Shintani, Y., Moriguchi, K., Encho, N., Kitagawa, K., Nakazawa, T., & Hashimoto, H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.732456 · Cited by 11
Kim, V., Wilson, S. M., & Woesner, M. E. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001941 · Cited by 11
Biased Signaling in Psychedelic Action
Wacker, D., & McCorvy, J. D. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-012545 · Cited by 10
Saunders, J. M., Muguruza, C., Sierra, S., Moreno, J. L., Callado, L. F., Meana, J. J., Beardsley, P. M., & González‐Maeso, J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102481 · Cited by 9
Self-citationHámor, P. U., Knackstedt, L. A., & Schwendt, M. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.10.005 · Cited by 11
Fukuyama, K., Motomura, E., & Okada, M. (2023) · Biomolecules · doi:10.3390/biom13091288 · Cited by 9
Tarakanov, A. O., Fuxé, K., & Borroto‐Escuela, D. O. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0734-2 · Cited by 9
“mGluR2-5HT2A Gonzalez-Maeso et al. (2008) Activation of mGluR2 inhibits hallucinogen-specific signaling of 5HT2A – – – * –”
Integrin triplets of marine sponges in human D2 receptor heteromers
Tarakanov, A. O., Fuxé, K., & Borroto‐Escuela, D. O. (2012) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2012.692119 · Cited by 9
Santini, M. A., Balu, D. T., Puhl, M. D., Hill‐Smith, T. E., Berg, A., Lucki, I., Mikkelsen, J. D., & Coyle, J. T. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.11.022 · Cited by 10
“To complicate matters, it was recently demonstrated that the mGluR2 receptor interacts with the 5-HT2AR, forming a heteromeric complex in which mGluR2 activation attenuates both 5-HT2AR-mediated c-fos mRNA expression and HTR [29].”
BackgroundGlutamate Neurotransmission in Psychotic Disorders and Substance Abuse
Kerner, B. (2009) · The Open Psychiatry Journal · doi:10.2174/1874354400903010001 · Cited by 10
“These changes were distinct from cellular responses after non-hallucinogenic drug binding, which did not involve mGluR2/3 activation [35, 36].”
Back to the future: Research renewed on the clinical utility of psychedelic drugs
Lieberman, J. A., & Shalev, D. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675755 · Cited by 11
“, lisuride) do not produce this psychedelic experience, it has been suggested that psychedelic drugs must bind to the 5-HT2A receptors in a special way, or exhibit functional selectivity or receptor bias (González-Maeso et al., 2008).”
BackgroundGarcía‐Bea, A., Bermúdez, I., Harrison, P. J., & Lane, T. A. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117715597 · Cited by 9
“[3H]LY341495 binding (ART1439 250, American Radiolabeled Chemicals) assays were carried out as previously described with minor modifications (González-Maeso et al., 2008).”
MethodMak, S. O. K., Zhang, L., & Chow, B. (2019) · The FASEB Journal · doi:10.1096/fj.201801732rr · Cited by 9
“This strategy has been demonstrated in analyzing the activity of mGluR2-5HT2aR heteromer (10, 48), inwhich the TM4 and TM5 ofmGluR2were found to be able to compete with receptor for interacting with 5HT2aR.”
MethodReceptor Pair for Schizophrenia
Sealfon, S. C., & González‐Maeso, J. (2008) · Pediatric Research · doi:10.1203/pdr.0b013e318180052a · Cited by 9
Self-citation
Metadata
- Authors
- González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J., & Sealfon, S. C.
- Affiliations
- University of the Basque Country (ES)
- University of Glasgow (GB)
- New York State Psychiatric Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Sealfon, Stuart C.
- ORCID
- Venue
- Nature
- Published
- 2008-02-24
- Volume
- 452
- Issue
- 7183
- Pages
- 93-97
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2743172
- OpenAlex
- W2024942419
- Cited by
- 803
- References
- 44
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 23 · 2023: 34 · 2022: 44 · 2021: 38 · 2020: 36 · 2019: 33 · 2018: 45 · 2017: 44 · 2016: 51 · 2015: 37 · 2014: 52 · 2013: 62 · 2012: 71
- FWCI
- 27.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- National Institute of Mental Health (U01MH083545)
- National Institute on Drug Abuse (T32DA007135, P01DA012923)
- National Institute of General Medical Sciences (T32GM062754)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- 5-HT2A receptor, mGluR2, metabotropic glutamate receptors, receptor complex, schizophrenia, psychosis, hallucinogens, LSD, psilocybin, cortical dysfunction, antipsychotic drug targets, postmortem brain
- MeSH terms
- Animals, Brain, Cell Line, Cells, Cultured, Hallucinogens, Humans, Models, Molecular, Protein Binding, Psychotic Disorders, Schizophrenia, Signal Transduction, Down-Regulation, Up-Regulation, Protein Structure, Tertiary, Receptors, Metabotropic Glutamate, Receptor, Serotonin, 5-HT2A, Multiprotein Complexes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.